News blog
Aim Awards 2007
- BY: Andrew Hore |
- POSTED: 21/10/2007 |
Silence Therapeutics was the only winner in the Aim Awards that was a micro company last year.
The biotech company was on the short list for the best technology award but that was not the one it won. Instead it won the first award of the night which was for the best performing share in the year up to the end of August 2007. The shares were nearly nine times the level they were 12 months earlier.
Silence Therapeutics is developing RNA interference (RNAi) molecules which can switch off or ‘silence’ genes that are linked to certain diseases. Silence became Europe’s leading RNAi company by acquiring Germany-based Atugen AG via a reverse takeover in July 2005. A deal with Astra Zeneca has helped to validate Silence’s technology.
It has been a bumpy ride for Silence which started out as Stanford Rook. It joined Aim more than a decade ago before changing its name to SR Pharma and subsequently transferring to the full list at the end of 1999. The share price at that point was slightly higher than it is now. It returned to Aim on 30 September 2004 and changed its name to Silence Therapeutics in May this year.
Aim Award winners
Best performing share over one year
Silence Therapeutics
Best performing share over five years
Griffin Mining
Best communication
Jelf Group
Best use of Aim
Spice
Best technology
Neuropharm Group
Aim transaction of the year
Mecom Group
Best research
Edison Investment Research
International company of the year
Leadcom Integrated Solutions Ltd
Best newcomer
Lamprell
Entrepreneur of the year
Ian Mattioli and Bob Woods - Mattioli Woods
Company of the year
Hamworthy
© 2024 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
- Browse by issue
- All issues
- Popular tags
- All tags
- AIM Micro feeds
Keep up to date with articles published at AIMMicro.com. Subscribe to AIM Micro RSS Feeds
|